Literature DB >> 24126586

Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis.

Shashank Gupta1, Keira A Cohen, Kathryn Winglee, Mamoudou Maiga, Bassirou Diarra, William R Bishai.   

Abstract

Drug efflux is an important resistance mechanism in Mycobacterium tuberculosis. We found that verapamil, an efflux inhibitor, profoundly decreases the MIC of bedaquiline and clofazimine to M. tuberculosis by 8- to 16-fold. This exquisite susceptibility was noted among drug-susceptible and drug-resistant clinical isolates. Thus, efflux inhibition is an important sensitizer of bedaquiline and clofazimine, and efflux may emerge as a resistance mechanism to these drugs.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24126586      PMCID： PMC3910722          DOI： 10.1128/AAC.01462-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil.

Authors:  R A Neal; J van Bueren; N G McCoy; M Iwobi
Journal:  Trans R Soc Trop Med Hyg       Date:  1989 Mar-Apr       Impact factor: 2.184

2.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

3.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

4.  Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Authors:  A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 5.  Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis.

Authors:  Pedro Eduardo Almeida da Silva; Andrea Von Groll; Anandi Martin; Juan Carlos Palomino
Journal:  FEMS Immunol Med Microbiol       Date:  2011-07-04

6.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.

Authors:  L Collins; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism.

Authors:  Kristin N Adams; Kevin Takaki; Lynn E Connolly; Heather Wiedenhoft; Kathryn Winglee; Olivier Humbert; Paul H Edelstein; Christine L Cosma; Lalita Ramakrishnan
Journal:  Cell       Date:  2011-03-03       Impact factor: 41.582

8.  Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex.

Authors:  Liliana Rodrigues; Diana Machado; Isabel Couto; Leonard Amaral; Miguel Viveiros
Journal:  Infect Genet Evol       Date:  2011-08-17       Impact factor: 3.342

9.  Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.

Authors:  R Rustomjee; A H Diacon; J Allen; A Venter; C Reddy; R F Patientia; T C P Mthiyane; T De Marez; R van Heeswijk; R Kerstens; A Koul; K De Beule; P R Donald; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

10.  Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis.

Authors:  Diana Machado; Isabel Couto; João Perdigão; Liliana Rodrigues; Isabel Portugal; Pedro Baptista; Bruno Veigas; Leonard Amaral; Miguel Viveiros
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240
View more
  42 in total

1.  Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

Authors:  Ciaran Skerry; Michael L Pinn; Natalie Bruiners; Richard Pine; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2014-05-22       Impact factor: 5.790

2.  The Pseudomonas aeruginosa efflux pump MexGHI-OpmD transports a natural phenazine that controls gene expression and biofilm development.

Authors:  Hassan Sakhtah; Leslie Koyama; Yihan Zhang; Diana K Morales; Blanche L Fields; Alexa Price-Whelan; Deborah A Hogan; Kenneth Shepard; Lars E P Dietrich
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

3.  Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis.

Authors:  Ji-Chan Jang; Yong-Gyun Jung; Jungil Choi; Hyunju Jung; Sungweon Ryoo
Journal:  J Microbiol       Date:  2017-04-20       Impact factor: 3.422

4.  Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.

Authors:  Ruben C Hartkoorn; Swapna Uplekar; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

Review 5.  Targeting efflux pumps to overcome antifungal drug resistance.

Authors:  Ann R Holmes; Tony S Cardno; J Jacob Strouse; Irena Ivnitski-Steele; Mikhail V Keniya; Kurt Lackovic; Brian C Monk; Larry A Sklar; Richard D Cannon
Journal:  Future Med Chem       Date:  2016-07-27       Impact factor: 3.808

Review 6.  Energy metabolism and drug efflux in Mycobacterium tuberculosis.

Authors:  Philippa A Black; Robin M Warren; Gail E Louw; Paul D van Helden; Thomas C Victor; Bavesh D Kana
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

7.  A Protein Complex from Human Milk Enhances the Activity of Antibiotics and Drugs against Mycobacterium tuberculosis.

Authors:  Virginia Meikle; Ann-Kristin Mossberg; Avishek Mitra; Anders P Hakansson; Michael Niederweis
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

8.  Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.

Authors:  Shashank Gupta; Sandeep Tyagi; William R Bishai
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

9.  Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.

Authors:  Jian Xu; Rokeya Tasneen; Charles A Peloquin; Deepak V Almeida; Si-Yang Li; Kala Barnes-Boyle; Yu Lu; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 10.  Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?

Authors:  Stephen K Field
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.